Constitutive IDO1 Expression in Human Tumors Is Driven by Cyclooxygenase-2 and Mediates Intrinsic Immune Resistance

Area of Science:

• Immunology
• Oncology
• Biochemistry

Background:

• Tumors evade immune destruction through various mechanisms.
• Cyclooxygenase-2 (COX-2) is implicated in immune suppression in melanoma, but its precise role is unclear.
• Indoleamine 2,3-dioxygenase 1 (IDO1) is an immunosuppressive enzyme that degrades tryptophan, contributing to immune evasion.

Purpose of the Study:

• To investigate the role of COX-2 in driving constitutive IDO1 expression in human tumors.
• To elucidate the signaling pathways linking COX-2 to IDO1 activation.
• To evaluate the therapeutic potential of COX-2 inhibition in enhancing anti-tumor immunity.

Main Methods:

• Analysis of COX-2 and IDO1 expression in seven human tumor lines.
• Investigating the signaling pathways (MAPK, PI3K, PKC) involved in COX-2/PGE2-mediated IDO1 activation.
• Treatment of human tumor xenografts with celecoxib (a COX-2 inhibitor) in immunodeficient mice reconstituted with human lymphocytes.

Main Results:

• COX-2 expression drives constitutive IDO1 expression in human tumor cells, dependent on prostaglandin E2 (PGE2) and autocrine signaling.
• IDO1 activation is mediated by the PKC and PI3K pathways, indirectly controlled by the MAPK pathway.
• Celecoxib treatment reduced IDO1 expression in ovarian SKOV3 xenografts and increased CD3+/CD8+ T-cell infiltration, promoting immune rejection.

Conclusions:

• COX-2 plays a critical role in the constitutive expression of IDO1 in human tumors.
• Targeting COX-2 with inhibitors can reduce IDO1 expression and enhance anti-tumor immune responses.
• COX-2 inhibitors represent a promising strategy to overcome immune suppression and improve immunotherapy efficacy in "cold" tumors lacking T-cell infiltration.